After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the ...

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

Whoop is whooping it up with a massive $575 million raise amid a strong start to the year for the fitness wearable.  | Whoop ...

KBP Biosciences is looking to reclaim ownership of the ill-fated heart drug ocedurenone from Novo Nordisk following a botched ...

The Waltham, Massachusetts-based company has entered into a reverse merger with the neuro-focused public company Cyclerion ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...

The firm analyzed more than 65,000 global trials conducted across over 350,000 sites in 186 countries. It found that 6.7% of ...

Carbone called BAP1 a “paradox” because of its seeming ability to both promote and slow cancer, depending on the ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Lipella Pharmaceuticals’ ambition to develop the first treatment for an inflammatory mouth condition has reached the end of ...

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune ...